keyword
MENU ▼
Read by QxMD icon Read
search

GARFIELD-AF

keyword
https://www.readbyqxmd.com/read/29370229/risk-factors-for-death-stroke-and-bleeding-in-28-628-patients-from-the-garfield-af-registry-rationale-for-comprehensive-management-of-atrial-fibrillation
#1
Jean-Pierre Bassand, Gabriele Accetta, Wael Al Mahmeed, Ramon Corbalan, John Eikelboom, David A Fitzmaurice, Keith A A Fox, Haiyan Gao, Samuel Z Goldhaber, Shinya Goto, Sylvia Haas, Gloria Kayani, Karen Pieper, Alexander G G Turpie, Martin van Eickels, Freek W A Verheugt, Ajay K Kakkar
BACKGROUND: The factors influencing three major outcomes-death, stroke/systemic embolism (SE), and major bleeding-have not been investigated in a large international cohort of unselected patients with newly diagnosed atrial fibrillation (AF). METHODS AND RESULTS: In 28,628 patients prospectively enrolled in the GARFIELD-AF registry with 2-year follow-up, we aimed at analysing: (1) the variables influencing outcomes; (2) the extent of implementation of guideline-recommended therapies in comorbidities that strongly affect outcomes...
2018: PloS One
https://www.readbyqxmd.com/read/29331969/temporal-trends-in-antithrombotic-treatment-of-real-world-uk-patients-with-newly-diagnosed-atrial-fibrillation-findings-from-the-garfield-af-registry
#2
Patricia N Apenteng, Haiyan Gao, Fd Richard Hobbs, David A Fitzmaurice
OBJECTIVE: To investigate evolving patterns in antithrombotic treatment in UK patients with newly diagnosed non-valvular atrial fibrillation (AF). DESIGN: Prospective, multicentre, international registry. SETTING: 186 primary care practices in the UK. PARTICIPANTS: 3482 participants prospectively enrolled in four sequential cohorts (cohort 2 (C2) n=830, diagnosed September 2011 to April 2013; cohort 3 (C3) n=902, diagnosed April 2013 to June 2014; cohort 4 (C4) n=850, diagnosed July 2014 to June 2015; cohort 5 (C5) n=900, diagnosed June 2015 to July 2016)...
January 13, 2018: BMJ Open
https://www.readbyqxmd.com/read/29281086/characteristics-of-patients-with-atrial-fibrillation-prescribed-antiplatelet-monotherapy-compared-with-those-on-anticoagulants-insights-from-the-garfield-af-registry
#3
Freek W A Verheugt, Haiyan Gao, Wael Al Mahmeed, Giuseppe Ambrosio, Pantep Angchaisuksiri, Dan Atar, Jean-Pierre Bassand, A John Camm, Frank Cools, John Eikelboom, Gloria Kayani, Toon Wei Lim, Frank Misselwitz, Karen S Pieper, Martin van Eickels, Ajay K Kakkar
Aims: Current atrial fibrillation (AF) guidelines discourage antiplatelet (AP) monotherapy as alternative to anticoagulants (ACs). Why AP only is still used is largely unknown. Methods and results: Factors associated with AP monotherapy prescription were analysed in GARFIELD-AF, a registry of patients with newly diagnosed (≤6 weeks) AF and ≥1 investigator-determined stroke risk factor. We analysed 51 270 patients from 35 countries enrolled into five sequential cohorts between 2010 and 2016...
February 7, 2018: European Heart Journal
https://www.readbyqxmd.com/read/29273652/improved-risk-stratification-of-patients-with-atrial-fibrillation-an-integrated-garfield-af-tool-for-the-prediction-of-mortality-stroke-and-bleed-in-patients-with-and-without-anticoagulation
#4
Keith A A Fox, Joseph E Lucas, Karen S Pieper, Jean-Pierre Bassand, A John Camm, David A Fitzmaurice, Samuel Z Goldhaber, Shinya Goto, Sylvia Haas, Werner Hacke, Gloria Kayani, Ali Oto, Lorenzo G Mantovani, Frank Misselwitz, Jonathan P Piccini, Alexander G G Turpie, Freek W A Verheugt, Ajay K Kakkar
OBJECTIVES: To provide an accurate, web-based tool for stratifying patients with atrial fibrillation to facilitate decisions on the potential benefits/risks of anticoagulation, based on mortality, stroke and bleeding risks. DESIGN: The new tool was developed, using stepwise regression, for all and then applied to lower risk patients. C-statistics were compared with CHA2 DS2 -VASc using 30-fold cross-validation to control for overfitting. External validation was undertaken in an independent dataset, Outcome Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)...
December 21, 2017: BMJ Open
https://www.readbyqxmd.com/read/29223431/international-trends-in-clinical-characteristics-and-oral-anticoagulation-treatment-for-patients-with-atrial-fibrillation-results-from-the-garfield-af-orbit-af-i-and-orbit-af-ii-registries
#5
MULTICENTER STUDY
Benjamin A Steinberg, Haiyan Gao, Peter Shrader, Karen Pieper, Laine Thomas, A John Camm, Michael D Ezekowitz, Gregg C Fonarow, Bernard J Gersh, Samuel Goldhaber, Sylvia Haas, Werner Hacke, Peter R Kowey, Jack Ansell, Kenneth W Mahaffey, Gerald Naccarelli, James A Reiffel, Alexander Turpie, Freek Verheugt, Jonathan P Piccini, Ajay Kakkar, Eric D Peterson, Keith A A Fox
Atrial fibrillation (AF) is the most common cardiac arrhythmia in the world. We aimed to provide comprehensive data on international patterns of AF stroke prevention treatment. METHODS: Demographics, comorbidities, and stroke risk of the patients in the GARFIELD-AF (n=51,270), ORBIT-AF I (n=10,132), and ORBIT-AF II (n=11,602) registries were compared (overall N=73,004 from 35 countries). Stroke prevention therapies were assessed among patients with new-onset AF (≤6 weeks). RESULTS: Patients from GARFIELD-AF were less likely to be white (63% vs 89% for ORBIT-AF I and 86% for ORBIT-AF II) or have coronary artery disease (19% vs 36% and 27%), but had similar stroke risk (85% CHA2 DS2 -VASc ≥2 vs 91% and 85%) and lower bleeding risk (11% with HAS-BLED ≥3 vs 24% and 15%)...
December 2017: American Heart Journal
https://www.readbyqxmd.com/read/29189853/-features-management-and-prognosis-of-chilean-patients-with-non-valvular-atrial-fibrillation-garfield-af-registry
#6
Ramón Corbalán, Carlos Conejeros, Carlos Rey, Benjamín Stockins, Germán Eggers, Carlos Astudillo, Fernando Lanas, Sergio Potthoff, César Houzvic, Humberto Montecinos, Gustavo Charme, Claudio Bugueño, Juan Aguilar, Germán Arriagada, Patricio Marín, Martín Larico
BACKGROUND: Atrial fibrillation (AF) is the most common cardiac arrhythmia and is associated with high rates of death, ischemic stroke and systemic embolism (SE). There is scarce information about clinical characteristics and use of anti-thrombotic therapies in Chilean patients with non-valvular AF. AIM: To describe the characteristics and 1-year outcomes of patients with recently diagnosed AF recruited in Chile into the prospective global GARFIELD-AF registry. MATERIAL AND METHODS: Between 2011-2016, we prospectively registered information of 971 patients recruited at 15 centers, 85% of them from the public system and 15% from the private sector...
August 2017: Revista Médica de Chile
https://www.readbyqxmd.com/read/29044400/erratum
#7
Keith A A Fox, Bernard J Gersh, Sory Traore, A John Camm, Gloria Kayani, Anders Krogh, Shweta Shweta, Ajay K Kakkar
No abstract text is available yet for this article.
October 1, 2017: European Heart Journal. Quality of Care & Clinical Outcomes
https://www.readbyqxmd.com/read/28950344/why-are-outcomes-different-for-registry-patients-enrolled-prospectively-and-retrospectively-insights-from-the-global-anticoagulant-registry-in-the-field-atrial-fibrillation-garfield-af
#8
Keith A A Fox, Gabriele Accetta, Karen S Pieper, Jean-Pierre Bassand, A John Camm, David A Fitzmaurice, Gloria Kayani, Ajay K Kakkar
Aims: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively...
January 1, 2018: European Heart Journal. Quality of Care & Clinical Outcomes
https://www.readbyqxmd.com/read/28927171/evolving-quality-standards-for-large-scale-registries-the-garfield-af-experience
#9
Keith A A Fox, Bernard J Gersh, Sory Traore, A John Camm, Gloria Kayani, Anders Krogh, Shweta Shweta, Ajay K Kakkar
Aims: Registries have the potential to capture treatment practices and outcomes in populations beyond the constraints of clinical trial settings. The value of data obtained depend critically upon robust quality standards (including source data verification [SDV] and training); features that are commonly absent from registries. This article outlines the quality standards developed for Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF). Methods and Results: GARFIELD-AF comprises ∼57 000 patients prospectively recruited over 6...
April 1, 2017: European Heart Journal. Quality of Care & Clinical Outcomes
https://www.readbyqxmd.com/read/28264833/impact-of-gender-on-event-rates-at-1-year-in-patients-with-newly-diagnosed-non-valvular-atrial-fibrillation-contemporary-perspective-from-the-garfield-af-registry
#10
MULTICENTER STUDY
A John Camm, Gabriele Accetta, Wael Al Mahmeed, Giuseppe Ambrosio, Samuel Z Goldhaber, Sylvia Haas, Petr Jansky, Gloria Kayani, Frank Misselwitz, Seil Oh, Ali Oto, Pekka Raatikainen, Jan Steffel, Martin van Eickels, Ajay K Kakkar
OBJECTIVES: Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) explored the impact of gender, risk factors and anticoagulant (AC) treatment on 1-year outcomes in patients with non-valvular atrial fibrillation (NVAF). DESIGN: GARFIELD-AF is a prospective non-interventional registry. SETTING: Investigator sites (n=1048) are representative of the care settings/locations in each of the 35 countries. PARTICIPANTS: Patients ≥18yrs with newly diagnosed (≤6 weeks' duration) NVAF and ≥1 investigator-determined stroke risk factors...
March 6, 2017: BMJ Open
https://www.readbyqxmd.com/read/27832408/erratum-to-the-global-anticoagulant-registry-in-the-field%C3%A2-atrial-fibrillation-garfield-af-exploring-the-changes-in-anticoagulant-practice-in-patients-with-non-valvular-atrial-fibrillation-in-the-netherlands
#11
https://www.readbyqxmd.com/read/27792741/quality-of-vitamin-k-antagonist-control-and-1-year-outcomes-in-patients-with-atrial-fibrillation-a-global-perspective-from-the-garfield-af-registry
#12
Sylvia Haas, Hugo Ten Cate, Gabriele Accetta, Pantep Angchaisuksiri, Jean-Pierre Bassand, A John Camm, Ramon Corbalan, Harald Darius, David A Fitzmaurice, Samuel Z Goldhaber, Shinya Goto, Barry Jacobson, Gloria Kayani, Lorenzo G Mantovani, Frank Misselwitz, Karen Pieper, Sebastian M Schellong, Janina Stepinska, Alexander G G Turpie, Martin van Eickels, Ajay K Kakkar
AIMS: Vitamin K antagonists (VKAs) need to be individually dosed. International guidelines recommend a target range of international normalised ratio (INR) of 2.0-3.0 for stroke prevention in atrial fibrillation (AF). We analysed the time in this therapeutic range (TTR) of VKA-treated patients with newly diagnosed AF in the ongoing, global, observational registry GARFIELD-AF. Taking TTR as a measure of the quality of patient management, we analysed its relationship with 1-year outcomes, including stroke/systemic embolism (SE), major bleeding, and all-cause mortality...
2016: PloS One
https://www.readbyqxmd.com/read/27647168/evolving-antithrombotic-treatment-patterns-for-patients-with-newly-diagnosed-atrial-fibrillation
#13
MULTICENTER STUDY
A John Camm, Gabriele Accetta, Giuseppe Ambrosio, Dan Atar, Jean-Pierre Bassand, Eivind Berge, Frank Cools, David A Fitzmaurice, Samuel Z Goldhaber, Shinya Goto, Sylvia Haas, Gloria Kayani, Yukihiro Koretsune, Lorenzo G Mantovani, Frank Misselwitz, Seil Oh, Alexander G G Turpie, Freek W A Verheugt, Ajay K Kakkar
OBJECTIVE: We studied evolving antithrombotic therapy patterns in patients with newly diagnosed non-valvular atrial fibrillation (AF) and ≥1 additional stroke risk factor between 2010 and 2015. METHODS: 39 670 patients were prospectively enrolled in four sequential cohorts in the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF): cohort C1 (2010-2011), n=5500; C2 (2011-2013), n=11 662; C3 (2013-2014), n=11 462; C4 (2014-2015), n=11 046...
February 15, 2017: Heart: Official Journal of the British Cardiac Society
https://www.readbyqxmd.com/read/27623681/rivaroxaban-real-world-evidence-validating-safety-and-effectiveness-in-clinical-practice
#14
Jan Beyer-Westendorf, A John Camm, Craig I Coleman, Sally Tamayo
Randomised controlled trials (RCTs) are considered the gold standard of clinical research as they use rigorous methodologies, detailed protocols, pre-specified statistical analyses and well-defined patient cohorts. However, RCTs do not take into account the complexity of real-world clinical decision-making. To tackle this, real-world data are being increasingly used to evaluate the long-term safety and effectiveness of a given therapy in routine clinical practice and in patients who may not be represented in RCTs, addressing key clinical questions that may remain...
September 28, 2016: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/27561277/the-global-anticoagulant-registry-in-the-field-atrial-fibrillation%C3%A2-garfield-af-exploring-the-changes-in-anticoagulant-practice-in-patients-with-non-valvular-atrial-fibrillation-in-the-netherlands
#15
V Ten Cate, H Ten Cate, F W A Verheugt
There are over 385,000 cases of atrial fibrillation (AF) in the Netherlands, with over 45,000 new cases each year. Among other things, AF patients are at high risk of stroke. Patients are often prescribed oral anticoagulation, such as vitamin K antagonists (VKA), to mitigate these risks. A recently introduced class of oral anticoagulants, non-vitamin K antagonists (NOAC), is quickly gaining currency in global clinical practice. This study provides insight into the changes these new drugs will bring about in Dutch clinical practice...
October 2016: Netherlands Heart Journal
https://www.readbyqxmd.com/read/27552578/vitamin-k-antagonist-control-in-patients-with-atrial-fibrillation-in-asia-compared-with-other-regions-of-the-world-real-world-data-from-the-garfield-af-registry
#16
MULTICENTER STUDY
Seil Oh, Shinya Goto, Gabriele Accetta, Pantep Angchaisuksiri, A John Camm, Frank Cools, Sylvia Haas, Gloria Kayani, Yukihiro Koretsune, Toon Wei Lim, Frank Misselwitz, Martin van Eickels, Ajay K Kakkar
OBJECTIVE: To compare the distribution of international normalized ratios (INRs) in patients receiving vitamin K antagonist (VKA) for newly diagnosed atrial fibrillation in Eastern and Southeastern Asia and in other regions of the world (ORW) represented in the ongoing, global observational study GARFIELD-AF. METHODS AND RESULTS: 3621 and 13,541 patients were recruited prospectively in 2010-2013 from Asia and ORW, respectively. At baseline, excluding patients with unknown antithrombotic treatment, 1356 (37...
November 15, 2016: International Journal of Cardiology
https://www.readbyqxmd.com/read/27357359/two-year-outcomes-of-patients-with-newly-diagnosed-atrial-fibrillation-results-from-garfield-af
#17
Jean-Pierre Bassand, Gabriele Accetta, Alan John Camm, Frank Cools, David A Fitzmaurice, Keith A A Fox, Samuel Z Goldhaber, Shinya Goto, Sylvia Haas, Werner Hacke, Gloria Kayani, Lorenzo G Mantovani, Frank Misselwitz, Hugo Ten Cate, Alexander G G Turpie, Freek W A Verheugt, Ajay K Kakkar
AIMS: The relationship between outcomes and time after diagnosis for patients with non-valvular atrial fibrillation (NVAF) is poorly defined, especially beyond the first year. METHODS AND RESULTS: GARFIELD-AF is an ongoing, global observational study of adults with newly diagnosed NVAF. Two-year outcomes of 17 162 patients prospectively enrolled in GARFIELD-AF were analysed in light of baseline characteristics, risk profiles for stroke/systemic embolism (SE), and antithrombotic therapy...
October 7, 2016: European Heart Journal
https://www.readbyqxmd.com/read/27071942/comparison-of-international-normalized-ratio-audit-parameters-in-patients-enrolled-in-garfield-af-and-treated-with-vitamin-k-antagonists
#18
COMPARATIVE STUDY
David A Fitzmaurice, Gabriele Accetta, Sylvia Haas, Gloria Kayani, Hector Lucas Luciardi, Frank Misselwitz, Karen Pieper, Hugo Ten Cate, Alexander G G Turpie, Ajay K Kakkar
Vitamin K antagonist (VKA) therapy for stroke prevention in atrial fibrillation (AF) requires monitoring of the international normalized ratio (INR). We evaluated the agreement between two INR audit parameters, frequency in range (FIR) and proportion of time in the therapeutic range (TTR), using data from a global population of patients with newly diagnosed non-valvular AF, the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF). Among 17 168 patients with 1-year follow-up data available at the time of the analysis, 8445 received VKA therapy (±antiplatelet therapy) at enrolment, and of these patients, 5066 with ≥3 INR readings and for whom both FIR and TTR could be calculated were included in the analysis...
August 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/26365937/stroke-prevention-in-atrial-fibrillation-patients-in-poland-and-other-european-countries-insights-from-the-garfield-af-registry
#19
MULTICENTER STUDY
Janina Stępińska, Elżbieta Kremis, Anna Konopka, Beata Wożakowska-Kapłon, Piotr Ruszkowski, Piotr Kukla, Gloria Kayani
BACKGROUND: Atrial fibrillation (AF) is the most common clinically-significant arrhythmia in the adult population, and it is a strong independent risk factor for cerebrovascular accidents. Patients with non-valvular AF are five times more likely to suffer a stroke. Despite the clear recommendations for anticoagulant therapy, many clinicians are still reluctant to provide routine oral anticoagulation to patients with AF, despite the potential clinical benefits. AIM: To compare Polish and European populations of patients with AF and the every-day practice of stroke prevention in Poland and in the rest of Europe...
2016: Kardiologia Polska
https://www.readbyqxmd.com/read/26069039/-garfield-af-first-data-on-healthcare-of-patients-with-atrial-fibrillation-in-germany
#20
Sylvia Haas
No abstract text is available yet for this article.
June 2015: Deutsche Medizinische Wochenschrift
keyword
keyword
85427
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"